How to Buy Teladoc Stock (TDOC) in 2026

Is Teladoc profitable?

Teladoc’s business is not currently profitable. The company recorded a net loss of roughly $200.3 million on sales of $2.53 billion in 2025. Sales were down roughly 2% annually, but the company’s net loss narrowed from roughly $1 billion in 2024. On the other hand, the company did record operating cash flow of $294.4 million and free cash flow of $166.9 million in 2025.

Notably, the company has never posted profitability on a full-year basis. Even when business was booming amid surging demand driven by the COVID-19 pandemic, Teladoc still did not achieve profitability. While the company has become more focused on operational efficiency rather than growth in subsequent years, frequent write-downs and impairment charges on the value of its assets have led to significant losses. The size of Teladoc’s impairment charges has been declining, and they are now having less of a negative impact on the company and its valuation — but goodwill adjustments have been a repeated drag on the telehealth specialist’s earnings statements.

Does Teladoc pay a dividend?

Teladoc stock does not pay a dividend. The company has never paid a dividend in its history, and its lack of profitability and free cash flow make it unlikely that shareholders will receive cash dividends anytime soon.

How to invest in Teladoc through ETFs

Because Teladoc is a small-cap stock operating in a niche corner of the healthcare industry, there aren’t many exchange-traded funds (ETFs) that include its stock as a major holding. Even so, there are ETFs that can provide investors with modest, diversified exposure to the stock market.

• iShares U.S. Healthcare Providers ETF (IHF -0.69%): This ETF is built around U.S. healthcare companies, including insurers and healthcare providers, and is built to track the Dow Jones U.S. Select Healthcare Providers Index. The fund has an expense ratio of 0.37%, and Teladoc makes up roughly 0.16% of its holdings.
• The Global X Telemedicine & Digital Health UCITS ETF (NASDAQ:EDOC): This ETF focuses on companies in telemedicine, healthcare analytics, healthcare devices, and digitization. It’s constructed to track the Solactive Telemedicine & Digital Health Index and has an expense ratio of 0.68%. Teladoc makes up roughly 1.4% of the fund’s holdings.

Will Teladoc stock split?

Teladoc is unlikely to carry out a stock split any time soon. Companies usually decide to implement a stock split when their share prices reach levels so high on a pure-dollar basis that they are psychologically unappealing to some investors. With Teladoc trading well under $10 per share in September 2026, there seems to be little reason for the company to split its stock.

If Teladoc were to fall well below its current valuation, the company could opt for a reverse stock split. To trade on the New York Stock Exchange, a company’s share price must be above $1 per share. But with Teladoc stock at roughly $6 per share in September 2026, a near-term reverse stock split also looks unlikely.

The bottom line

Teladoc is a company that’s still facing some big challenges. The telehealth specialist’s revenue has continued to decline, and it has recorded meaningful goodwill impairment charges that are adding to its losses.

On the other hand, the stock is already heavily beaten down — and the business’s operating and free cash flow suggest that shares could have significant upside potential if the company can return to even modest sales growth and trim operating expenses. Teladoc is a speculative turnaround play with risks despite its depressed valuation, but shares could deliver big gains if business fundamentals improve.